市場調査レポート

免疫化学の世界市場

Immunochemicals

発行 Global Industry Analysts, Inc. 商品コード 240193
出版日 ページ情報 英文 633 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
免疫化学の世界市場 Immunochemicals
出版日: 2012年04月01日 ページ情報: 英文 633 Pages
概要

当レポートでは、免疫化学の世界市場を製品部門別に分析し、米国/カナダ/日本/欧州/中国/その他の地域についての包括的な地域別分析を提供し、2009-2017年間の年間業績を推定/予測するとともに6年間の歴史的分析、及び主要/ニッチプレーヤ129社の企業プロファイルを盛り込み、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリ

第3章 業界概要

  • 免疫化学への需要増大
  • 抗体:創薬/研究における重大な役割
  • 代替アプローチに押される動物系技術
  • 新興市場が提供する多大な可能性
  • カスタム抗体:研究アプリケーションの支持を受ける
  • 研究用抗体:治療用抗体市場の可能性につながる
  • 学界からの脅威に直面する抗体製造業者
  • 競合的シナリオ
  • 世界の免疫化学市場プレーヤの競合に影響している要因:購入者の重要性による評価

第4章 免疫化学の紹介

  • 免疫化学
  • 免疫化学のタイプ
  • カタログ抗体
  • カスタム抗体
  • 免疫化学のアプリケーション
  • 医療
  • 環境的科学
  • 作物保護とバイオテクノロジー
  • 主要研究分野
  • 世界の免疫化学市場における研究に使用される一般的技術

第5章 抗体:入門

  • 抗体の紹介
  • 一次/二次抗体
  • 研究アプリケーションにおける抗体
  • モノクローナル抗体
  • ポリクローナル抗体
  • 結合抗体

第6章 モノクローナル抗体市場:概要

  • イントロダクション
  • アジア:収益性の高い市場
  • 中国:最速成長市場
  • 治療/診断アプリケーションにおける甚大な成長
  • ヒト化/完全ヒト抗体への移行
  • 抗体生産プロセスにおける進歩と課題
  • モノクローナル抗体の将来:小型化と生産費用の減少
  • 市場に直面している課題

第7章 製品紹介/革新

第8章 最近の業界活動

第9章 世界の主要プレーヤへの焦点

第10章 世界市場展望

  • 米国
  • カナダ
  • 日本
  • 欧州
  • 中国
  • その他の地域

第11章 競合状況

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6052

This report analyzes the worldwide markets for Immunochemicals in US$ million by the following product segments - Catalog Antibodies, and Custom Antibodies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, China, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 129 companies including many key and niche players such as Abbott Diagnostics, Advanced ImmunoChemical, Beckman Coulter, Inc., BioCat GmbH, BIOTREND Chemikalien GmbH, Bio-Rad Laboratories, Inc., Dako, Life Technologies Corporation, Maine Biotechnology Services, Meridian Life Science , Inc., Millipore Corporation, MitoSciences, Inc., MorphoSys AG, Randox Laboratories Ltd., Roche Group, Rockland Immunochemicals, Sigma-Aldrich Co., and Trinity Biotech, PLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
    • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Catalog Antibodies
    • Custom Antibodies

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Escalating Demand for Immunochemicals
  • Antibodies: Critical Role in Drug Discovery and Research
  • Animal-Based Technologies Lose Ground to Alternative Approaches
  • Emerging Markets Offer Huge Potential
  • Custom Antibodies: Finding Favor in Research Applications
  • Research Antibodies- Linked to Prospects of Therapeutic Antibody Market
  • Antibody Manufacturers Face Threat from Academics Sector
    • Table 1: Global Immunochemicals Market (2010): Percentage Share Breakdown of Revenues by Sector for Academic and Pharmaceutical & Biotech (includes corresponding Graph/Chart)
  • Competitive Scenario
  • Factors Affecting Competitiveness of Players in the Global Immunochemicals Market - Ranked by Importance for Purchasers

2. AN INTRODUCTION TO IMMUNOCHEMICALS

  • Immunochemicals
  • Types of Immunochemicals
  • Catalog Antibodies
  • Custom Antibodies
  • Applications of Immunochemicals
  • Healthcare
  • Environmental Science
  • Crop Protection and Biotechnology
  • Leading Research Areas
    • Table 2: Leading Research Areas in the Global Immunochemicals Market (2010): Percentage Share Breakdown for Immunology, Neurobiology, Signal Transduction, Developmental Biology, Cardiovascular, Virology, and Others (includes corresponding Graph/Chart)
  • Common Techniques Used for Research in the Global Immunochemicals Market

3. ANTIBODIES - A PRIMER

  • Introduction to Antibodies
  • Primary and Secondary Antibodies
  • Antibodies in Research Applications
    • Table 3: Antibody Usage in Research Sector (2009): Percentage Share Breakdown of Revenues by Platform for Flow Cytometry, ELISA, Protein Arrays, and Others (includes corresponding Graph/Chart)
  • Monoclonal Antibodies
  • Properties
  • Applications
  • Polyclonal Antibodies
  • Production Process
  • Properties
  • Applications
  • Conjugate Antibodies

4. MONOCLONAL ANTIBODY MARKET - AN OVERVIEW

  • Introduction
  • Asia: A Lucrative Market
  • China - The Fastest Growing mAb Market
  • Significant Growth in Therapeutic and Diagnostic Applications
  • Shift Towards Humanized and Fully Human Antibodies
  • Advancements & Challenges in Antibody Production Processes
  • Future of mAbs - Smaller and Inexpensive to Produce
    • Structurally Modified Full-Size mAbs - Next Type of mAbs to Hit the Market
  • MAb Fragments
  • Challenges Facing mAb Market
  • High Manufacturing and Development Cost
  • Mode of Administration
  • Strong Competition
  • Expiration of Patents
  • Immunogenicity
  • Regulatory Concerns
  • Competitive Scenario

5. PRODUCT INTRODUCTIONS/INNOVATIONS

  • AMSBIO Introduces Rabbit Monoclonal and Polyclonal Antibodies Portfolio
  • Immunocore Initiates Clinical Trials for IMCgp100
  • bioMerieux Introduces VIDAS® EBV
  • PerkinElmer Introduces LANCE® Ultra Assay Products
  • Radiometer Introduces NT-proBNP in AQT90 FLEX Immunoassay Analyzer Test Menu
  • Radiometer Introduces C-Reactive Protein in AQT90 FLEX Immunoassay Analyzer
  • Diagnostic Biosystems Introduces IVD Labeled Staining Reagents Range
  • Radiometer Adds β - hCG Pregnancy Marker to AQT90 FLEX Immunoassay Analyzer
  • Qualigen Introduces FastPack® hCG Immunoassay
  • Enterix Launches InSure® Quik F I T™ Fecal Immunochemical Test
  • Amgen Introduces Vectibix
  • Trevigen Introduces Mouse Monoclonal Antibody

6. RECENT INDUSTRY ACTIVITY

  • Abcam Takes Over MitoSciences
  • Rockland Immunochemicals Receives Grants from NIH
  • Bio-Rad Laboratories Acquires Diagnostic Businesses from Biotest
  • Beckman Coulter Takes Over Diagnostic Business of Olympus
  • Roche Takes Over Genentech
  • GED Capital to Acquire Majority Stake in Diamedix
  • PerkinElmer Enters into Collaboration with BioLegend
  • Abbott Inks Agreement with BG Medicine
  • Ortho Clinical Diagnostics Receives FDA Approval for VITROS® HBsAg Assay
  • Athera Inks Agreements with Oxford Biosystems and Asbach Medical Products
  • CTI Acquires AVANT Immunotherapeutics
  • Clinical Genomics Enters into Global License Agreement with Quest Diagnostics
  • Sigma-Aldrich Obtains Seppro Affinity Depletion Technology from GenWay Biotech
  • Siemens to Merge with Siemens Healthcare Diagnostics
  • Merck Acquires Bangalore Genei
  • Commonwealth Biotechnologies to Purchase GL Biochem
  • Intercell Takes Over Iomai
  • Thermo Fisher Scientific Takes Over Open Biosystems
  • Thermo Fisher Scientific Acquires Affinity BioReagents
  • Daiichi Sankyo Takes Over U3 Pharma
  • IMUC Completes Molecular Antibody Technology Acquisition
  • EUSA Pharma to Take Over Cytogen
  • Access Pharmaceuticals Acquires Somanta Pharmaceuticals
  • Genmab Enters into Antibody Research Collaboration with Pepscan
  • BTI Enters into an Agreement with Raven
  • Eusa Sells Antibody Research Business
  • AVANIR Inks Definitive Agreement to Divest Anthrax Antibodies
  • CG Therapeutics and UoW Agree for Joint Monoclonal Antibody Program
  • SDI to Develop mAbs for SAIC-F and NCI
  • Morphotek and HMI in Licensing Agreement
  • Amgen Enters into Licensing Agreement with Kyowa Hakko
  • Dyax and Sanofi-Aventis Sign Agreements
  • HGS Enters into Antibody Collaboration Agreement with Xencor
  • Biogen Partners with Genentech and Roche for Development of GA-101
  • Tecan Commences Operations at Refurbished Facility

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Diagnostics (UK)
  • Advanced ImmunoChemical (US)
  • Beckman Coulter, Inc. (US)
  • BioCat GmbH (Germany)
  • BIOTREND Chemikalien GmbH (Germany)
  • Bio-Rad Laboratories, Inc. (US)
  • Dako (Denmark)
  • Life Technologies Corporation (US)
  • Maine Biotechnology Services (US)
  • Meridian Life Science®, Inc. (US)
  • Millipore Corporation (US)
  • MitoSciences, Inc. (US)
  • MorphoSys AG (Germany)
  • Randox Laboratories Ltd. (UK)
  • Roche Group (Switzerland)
  • Rockland Immunochemicals (US)
  • Sigma-Aldrich Co (US)
  • Trinity Biotech, PLC (Ireland)

8. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current & Future Analysis for Immunochemicals by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 5: World Historic Review for Immunochemicals by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 6: World 15-Year Perspective for Immunochemicals by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, China and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 7: World Recent Past, Current & Future Analysis for Catalog Antibodies by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 8: World Historic Review for Catalog Antibodies by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 9: World 15-Year Perspective for Catalog Antibodies by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, China and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 10: World Recent Past, Current & Future Analysis for Custom Antibodies by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Custom Antibodies by Geographic Region - US, Canada, Japan, Europe, China and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Custom Antibodies by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, China and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • Market Analysis
    • Table 13: US Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 14: US Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 15: US 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analytics
    • Table 16: Canadian Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 17: Canadian Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 18: Canadian 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 19: Japanese Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 20: Japanese Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 21: Japanese 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analytics
    • Table 22: European Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 23: European Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 24: European 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

5. CHINA

  • A. Market Analysis
    • A Rapidly Expanding mAb Market
      • Strengths and Opportunities
      • Target-Specific Nature of Monoclonal Antibodies
      • Rising Incidence of Cancer & Age-Related Conditions: Potential Opportunity
      • Manufacturing Advancements
      • High Cost of mAb Treatment in the EU and US
  • B. Market Analytics
    • Table 25: Chinese Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: Chinese Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 27: Chinese 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Asia Offers Enormous Opportunities for mAb Market
  • B. Market Analytics
    • Table 28: Rest of World Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 29: Rest of World Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 30: Rest of World 15-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top